CleftGeneDB-Search

Gene: NAT2

Basic information

Tag	Content
Uniprot ID	P11245; O43637; O60654; O60655; Q13146; Q16697; Q2MLE4; Q2MLF5; Q2MLG8; Q2MLJ6; Q2MLK4; Q2MLK6; Q2MLN7; Q6LET4; Q86XS0; Q86XS1; Q96KY8; Q96T64; Q96T65; Q9H220;
Entrez ID	10
Genbank protein ID	ABC26095.1; ABC26153.1; ABC26121.1; ABC26044.1; ABC26163.1; AAC14118.1; ABC26089.1; ABC26097.1; ABC26139.1; ABC26119.1; ABC26100.1; ABC26164.1; ABC26060.1; ABC26127.1; ABC26118.1; AAO73562.1; ABC26145.1; ABC26143.1; ABC26042.1; ABC26047.1; ABC26175.1; ABC26181.1; ABC26126.1; ABC26076.1; ABC26088.1; ABC26133.1; ABC26169.1; ABC26115.1; ABC26160.1; ABC26158.1; ABC26041.1; ABC26077.1; ABC26157.1; AAA64584.1; ABC26062.1; ABC26161.1; AAO73561.1; ABC26103.1; ABC26132.1; ABC26110.1; ABC26182.1; ABC26069.1; ABC26073.1; ABC26104.1; ABC26067.1; ABC26050.1; ABC26144.1; AAC14117.1; ABC26122.1; ABC26056.1; ABC26107.1; ABC26148.1; ABC26188.1; ABC26155.1; ABC26180.1; ABC26112.1; ABC26032.1; ABC26081.1; ABC26092.1; ABC26167.1; ABC26168.1; ABC26173.1; ABC26156.1; AAA98976.1; ABC26033.1; ABC26074.1; ABC26149.1; CAA32802.1; ABC26152.1; ABC26165.1; ABC26128.1; ABC26063.1; ABC26057.1; ABC26043.1; ABC26048.1; ABC26086.1; ABC26174.1; ABC26123.1; ABC26141.1; ABC26166.1; BAA01641.1; ABC26087.1; ABC26125.1; AAC03773.1; CAG28559.1; ABC26053.1; ABC26134.1; ABC26142.1; ABC26120.1; ABC26179.1; ABC26061.1; ABC26079.1; ABC26101.1; AAP81164.1; ABC26045.1; ABC26098.1; AAK51710.1; ABC26186.1; ABC26091.1; ABC26037.1; ABC26178.1; ABC26150.1; ABC26140.1; ABC26171.1; ABC26108.1; ABC26136.1; ABC26184.1; AAH67218.1; ABC26190.1; ABC26035.1; ABC26065.1; ABC26072.1; ABC26078.1; ABC26090.1; ABC26162.1; ABC26071.1; BAA01642.1; ABC26113.1; ABC26151.1; ABC26039.1; ABC26082.1; ABC26183.1; ABC26116.1; ABC26147.1; ABC26191.1; ABC26117.1; ABC26102.1; AAG34181.1; ABC26034.1; ABC26040.1; ABC26130.1; BAA14094.1; ABC26064.1; ABC26146.1; ABC26114.1; BAA01640.1; ABC26083.1; ABC26084.1; ABC26075.1; ABC26093.1; ABC26036.1; BAA14096.1; ABC26185.1; ABC26051.1; ABC26059.1; ABC26154.1; ABC26106.1; ABC26189.1; ABC26177.1; ABC26159.1; ABC26172.1; ABC26138.1; ABC26111.1; ABC26129.1; ABC26058.1; ABC26038.1; ABC26055.1; ABC26068.1; ABC26096.1; ABC26049.1; ABC26099.1; ABC26054.1; ABC26046.1; AAH15878.1; ABC26070.1; ABC26137.1; ABC26176.1; ABC26066.1; AAK51711.1; ABC26187.1; ABC26170.1; ABC26085.1; ABC26094.1; ABC26105.1; ABC26124.1; AAA64585.1; AAA59906.1; ABC26135.1; ABC26052.1; ABC26131.1; ABC26080.1; ABC26109.1;
Genbank nucleotide ID	XM_017012938.1; NM_000015.2;
Ensembl protein ID	ENSP00000286479
Ensembl nucleotide ID	ENSG00000156006
Gene name	Arylamine N-acetyltransferase 2
Gene symbol	NAT2
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Manually collected
Reference	17160896; 23660777;
Functional description	Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens.
Sequence	MDIEAYFERI GYKNSRNKLD LETLTDILEH QIRAVPFENL NMHCGQAMEL GLEAIFDHIV 60 RRNRGGWCLQ VNQLLYWALT TIGFQTTMLG GYFYIPPVNK YSTGMVHLLL QVTIDGRNYI 120 VDAGSGSSSQ MWQPLELISG KDQPQVPCIF CLTEERGIWY LDQIRREQYI TNKEFLNSHL 180 LPKKKHQKIY LFTLEPRTIE DFESMNTYLQ TSPTSSFITT SFCSLQTPEG VYCLVGFILT 240 YRKFNYKDNT DLVEFKTLTE EEVEEVLKNI FKISLGRNLV PKPGDGSLTI

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
2PFR

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Species	Evidence	Details
1:1 ortholog	NAT2	10	P11245	Homo sapiens	Publication	More>>
1:1 ortholog	Nat1		A0A1D5RLG2	Mus musculus	Prediction	More>>
1:1 ortholog	NAT2	464024	H2QVT5	Pan troglodytes	Prediction	More>>
1:1 ortholog	Nat1	116631	P50297	Rattus norvegicus	Prediction	More>>

Identified variants/mutations related to cleft phenotype

Gene symbol	Significant Variants/SNPS	Methods	PubMed ID
NAT2	rs1041983C>T	Genotyping	23660777
NAT2	rs1799930; c.590G>A	Genotyping	17160896

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs754150699	p.Asp2Gly	missense variant	-	NC_000008.11:g.18400008A>G	ExAC,gnomAD
rs200893121	p.Ile3Val	missense variant	-	NC_000008.11:g.18400010A>G	1000Genomes
rs186884477	p.Ile3Thr	missense variant	-	NC_000008.11:g.18400011T>C	1000Genomes,ExAC,TOPMed,gnomAD
rs186884477	p.Ile3Asn	missense variant	-	NC_000008.11:g.18400011T>A	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu4Val	missense variant	-	NC_000008.11:g.18400014A>T	NCI-TCGA
rs1435840670	p.Tyr6His	missense variant	-	NC_000008.11:g.18400019T>C	gnomAD
COSM6112854	p.Phe7Tyr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400023T>A	NCI-TCGA Cosmic
COSM3646974	p.Arg9Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400029G>A	NCI-TCGA Cosmic
COSM1097664	p.Arg9Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400029G>T	NCI-TCGA Cosmic
rs72466456	p.Ile10Asn	missense variant	-	NC_000008.11:g.18400032T>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs72466456	p.Ile10Thr	missense variant	-	NC_000008.11:g.18400032T>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs72466456	p.Ile10Ser	missense variant	-	NC_000008.11:g.18400032T>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs747536177	p.Gly11Val	missense variant	-	NC_000008.11:g.18400035G>T	ExAC,gnomAD
rs755689546	p.Tyr12Cys	missense variant	-	NC_000008.11:g.18400038A>G	ExAC,gnomAD
rs1281741349	p.Lys13Arg	missense variant	-	NC_000008.11:g.18400041A>G	gnomAD
rs777235619	p.Lys13Asn	missense variant	-	NC_000008.11:g.18400042G>T	ExAC,TOPMed,gnomAD
rs770525419	p.Asn14His	missense variant	-	NC_000008.11:g.18400043A>C	ExAC
rs774237368	p.Asn14Lys	missense variant	-	NC_000008.11:g.18400045C>G	ExAC,gnomAD
rs1258543620	p.Ser15Thr	missense variant	-	NC_000008.11:g.18400046T>A	gnomAD
rs745585836	p.Arg16Ser	missense variant	-	NC_000008.11:g.18400051G>T	ExAC,gnomAD
rs928522570	p.Arg16Thr	missense variant	-	NC_000008.11:g.18400050G>C	TOPMed,gnomAD
rs201339185	p.Asn17Lys	missense variant	-	NC_000008.11:g.18400054C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1475615331	p.Leu19Trp	missense variant	-	NC_000008.11:g.18400059T>G	TOPMed
rs532310930	p.Asp20Tyr	missense variant	-	NC_000008.11:g.18400061G>T	1000Genomes,ExAC,TOPMed,gnomAD
rs760627448	p.Leu21Ter	stop gained	-	NC_000008.11:g.18400065T>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Leu21Phe	missense variant	-	NC_000008.11:g.18400066G>C	NCI-TCGA
rs764315394	p.Thr23Ile	missense variant	-	NC_000008.11:g.18400071C>T	ExAC,gnomAD
rs1464413878	p.Thr23Pro	missense variant	-	NC_000008.11:g.18400070A>C	TOPMed
rs45477599	p.Leu24Ile	missense variant	-	NC_000008.11:g.18400073T>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs45477599	p.Leu24Ile	missense variant	-	NC_000008.11:g.18400073T>A	UniProt,dbSNP
VAR_018853	p.Leu24Ile	missense variant	-	NC_000008.11:g.18400073T>A	UniProt
rs1204993451	p.Thr25Pro	missense variant	-	NC_000008.11:g.18400076A>C	TOPMed
rs1325562681	p.Asp26Asn	missense variant	-	NC_000008.11:g.18400079G>A	gnomAD
rs765487420	p.Ile27Leu	missense variant	-	NC_000008.11:g.18400082A>C	ExAC,TOPMed,gnomAD
rs1275931651	p.Leu28His	missense variant	-	NC_000008.11:g.18400086T>A	gnomAD
COSM750180	p.Glu29Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400090G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Ile32Met	missense variant	-	NC_000008.11:g.18400099C>G	NCI-TCGA
rs138592670	p.Arg33Gln	missense variant	-	NC_000008.11:g.18400101G>A	ESP,ExAC,TOPMed,gnomAD
rs763283305	p.Arg33Trp	missense variant	-	NC_000008.11:g.18400100C>T	ExAC,TOPMed,gnomAD
rs752047953	p.Val35Ile	missense variant	-	NC_000008.11:g.18400106G>A	ExAC,TOPMed,gnomAD
rs752047953	p.Val35Phe	missense variant	-	NC_000008.11:g.18400106G>T	ExAC,TOPMed,gnomAD
rs199780526	p.Val35Ala	missense variant	-	NC_000008.11:g.18400107T>C	1000Genomes
rs752047953	p.Val35Leu	missense variant	-	NC_000008.11:g.18400106G>C	ExAC,TOPMed,gnomAD
rs377338395	p.Pro36Ala	missense variant	-	NC_000008.11:g.18400109C>G	ESP,ExAC,TOPMed,gnomAD
rs377338395	p.Pro36Thr	missense variant	-	NC_000008.11:g.18400109C>A	ESP,ExAC,TOPMed,gnomAD
rs753310036	p.Phe37Ser	missense variant	-	NC_000008.11:g.18400113T>C	ExAC,TOPMed,gnomAD
rs1272204007	p.Phe37Leu	missense variant	-	NC_000008.11:g.18400112T>C	gnomAD
rs149283608	p.Asn41Tyr	missense variant	-	NC_000008.11:g.18400124A>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs886633825	p.Met42Leu	missense variant	-	NC_000008.11:g.18400127A>T	TOPMed,gnomAD
rs1405525958	p.Met42Thr	missense variant	-	NC_000008.11:g.18400128T>C	TOPMed
rs1175197943	p.His43Pro	missense variant	-	NC_000008.11:g.18400131A>C	gnomAD
rs1411878664	p.Cys44Ser	missense variant	-	NC_000008.11:g.18400134G>C	TOPMed
rs771801023	p.Gly45Val	missense variant	-	NC_000008.11:g.18400137G>T	ExAC,TOPMed,gnomAD
rs771801023	p.Gly45Glu	missense variant	-	NC_000008.11:g.18400137G>A	ExAC,TOPMed,gnomAD
rs779874333	p.Gln46His	missense variant	-	NC_000008.11:g.18400141A>T	ExAC,gnomAD
rs1463045225	p.Ala47Val	missense variant	-	NC_000008.11:g.18400143C>T	gnomAD
rs1463045225	p.Ala47Asp	missense variant	-	NC_000008.11:g.18400143C>A	gnomAD
rs1165911161	p.Met48Val	missense variant	-	NC_000008.11:g.18400145A>G	TOPMed
rs1189346481	p.Glu49Lys	missense variant	-	NC_000008.11:g.18400148G>A	TOPMed,gnomAD
rs111750824	p.Leu50Met	missense variant	-	NC_000008.11:g.18400151T>A	gnomAD
rs72466457	p.Gly51Val	missense variant	-	NC_000008.11:g.18400155G>T	TOPMed,gnomAD
NCI-TCGA novel	p.Leu52Phe	missense variant	-	NC_000008.11:g.18400159A>T	NCI-TCGA
rs1473213000	p.Glu53Gln	missense variant	-	NC_000008.11:g.18400160G>C	TOPMed,gnomAD
NCI-TCGA novel	p.Ala54Val	missense variant	-	NC_000008.11:g.18400164C>T	NCI-TCGA
COSM1455898	p.Ala54Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400163G>A	NCI-TCGA Cosmic
rs78003756	p.Asp57Tyr	missense variant	-	NC_000008.11:g.18400172G>T	-
rs776854665	p.Asp57Gly	missense variant	-	NC_000008.11:g.18400173A>G	ExAC,gnomAD
rs773371959	p.Ile59Thr	missense variant	-	NC_000008.11:g.18400179T>C	ExAC,TOPMed,gnomAD
rs773371959	p.Ile59Asn	missense variant	-	NC_000008.11:g.18400179T>A	ExAC,TOPMed,gnomAD
rs374728016	p.Ile59Phe	missense variant	-	NC_000008.11:g.18400178A>T	ESP,ExAC,gnomAD
rs779910396	p.Asn63Ser	missense variant	-	NC_000008.11:g.18400191A>G	ExAC,TOPMed,gnomAD
rs1805158	p.Arg64Trp	missense variant	-	NC_000008.11:g.18400193C>T	ExAC,TOPMed,gnomAD
rs1801279	p.Arg64Gln	missense variant	-	NC_000008.11:g.18400194G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1019316375	p.Gly65Asp	missense variant	-	NC_000008.11:g.18400197G>A	TOPMed,gnomAD
rs1019316375	p.Gly65Val	missense variant	-	NC_000008.11:g.18400197G>T	TOPMed,gnomAD
COSM3646976	p.Gly66Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400200G>A	NCI-TCGA Cosmic
rs756821699	p.Trp67Leu	missense variant	-	NC_000008.11:g.18400203G>T	ExAC,TOPMed,gnomAD
rs201345576	p.Trp67Arg	missense variant	-	NC_000008.11:g.18400202T>C	1000Genomes,gnomAD
rs1476310549	p.Trp67Cys	missense variant	-	NC_000008.11:g.18400204G>T	gnomAD
rs1476310549	p.Trp67Ter	stop gained	-	NC_000008.11:g.18400204G>A	gnomAD
NCI-TCGA novel	p.Gln70His	missense variant	-	NC_000008.11:g.18400213G>T	NCI-TCGA
COSM3646977	p.Gln70Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000008.11:g.18400211C>T	NCI-TCGA Cosmic
rs201080763	p.Asn72Ser	missense variant	-	NC_000008.11:g.18400218A>G	ExAC,TOPMed,gnomAD
rs1408322773	p.Gln73Ter	stop gained	-	NC_000008.11:g.18400220C>T	gnomAD
rs750089838	p.Gln73His	missense variant	-	NC_000008.11:g.18400222A>C	ExAC,gnomAD
rs1371741216	p.Leu75Val	missense variant	-	NC_000008.11:g.18400226C>G	TOPMed,gnomAD
rs72466459	p.Tyr76Ter	stop gained	-	NC_000008.11:g.18400231C>A	gnomAD
rs72466459	p.Tyr76Ter	stop gained	-	NC_000008.11:g.18400231C>G	gnomAD
rs1311450114	p.Trp77Ter	stop gained	-	NC_000008.11:g.18400233G>A	TOPMed,gnomAD
rs1284492798	p.Thr80Ser	missense variant	-	NC_000008.11:g.18400242C>G	gnomAD
rs1422696182	p.Thr81Ala	missense variant	-	NC_000008.11:g.18400244A>G	TOPMed
NCI-TCGA novel	p.Thr81Ile	missense variant	-	NC_000008.11:g.18400245C>T	NCI-TCGA
rs951834305	p.Thr81Lys	missense variant	-	NC_000008.11:g.18400245C>A	gnomAD
rs1342819768	p.Ile82Phe	missense variant	-	NC_000008.11:g.18400247A>T	gnomAD
rs561124342	p.Gly83Val	missense variant	-	NC_000008.11:g.18400251G>T	1000Genomes,ExAC,TOPMed,gnomAD
rs561124342	p.Gly83Ala	missense variant	-	NC_000008.11:g.18400251G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs746734312	p.Gly83Ser	missense variant	-	NC_000008.11:g.18400250G>A	ExAC,TOPMed,gnomAD
rs746734312	p.Gly83Cys	missense variant	-	NC_000008.11:g.18400250G>T	ExAC,TOPMed,gnomAD
rs773321494	p.Phe84Tyr	missense variant	-	NC_000008.11:g.18400254T>A	ExAC,gnomAD
rs1260133999	p.Gln85Ter	stop gained	-	NC_000008.11:g.18400256C>T	gnomAD
rs763106203	p.Gln85His	missense variant	-	NC_000008.11:g.18400258G>C	ExAC,gnomAD
rs1474441417	p.Gln85Pro	missense variant	-	NC_000008.11:g.18400257A>C	gnomAD
rs771145519	p.Thr86Asn	missense variant	-	NC_000008.11:g.18400260C>A	ExAC,gnomAD
rs774706631	p.Met88Val	missense variant	-	NC_000008.11:g.18400265A>G	ExAC,TOPMed,gnomAD
rs774706631	p.Met88Leu	missense variant	-	NC_000008.11:g.18400265A>C	ExAC,TOPMed,gnomAD
rs1172380462	p.Met88Thr	missense variant	-	NC_000008.11:g.18400266T>C	gnomAD
rs1490596479	p.Gly90Glu	missense variant	-	NC_000008.11:g.18400272G>A	TOPMed
rs759840221	p.Gly90Arg	missense variant	-	NC_000008.11:g.18400271G>A	ExAC,TOPMed,gnomAD
rs555947824	p.Tyr94Phe	missense variant	-	NC_000008.11:g.18400284A>T	gnomAD
rs1427989661	p.Ile95Thr	missense variant	-	NC_000008.11:g.18400287T>C	gnomAD
rs948085566	p.Ile95Met	missense variant	-	NC_000008.11:g.18400288C>G	TOPMed,gnomAD
rs761144507	p.Pro96Leu	missense variant	-	NC_000008.11:g.18400290C>T	ExAC,gnomAD
rs761144507	p.Pro96His	missense variant	-	NC_000008.11:g.18400290C>A	ExAC,gnomAD
rs1233452008	p.Pro97Ala	missense variant	-	NC_000008.11:g.18400292C>G	gnomAD
rs1321612090	p.Pro97Leu	missense variant	-	NC_000008.11:g.18400293C>T	TOPMed
rs927916278	p.Val98Ile	missense variant	-	NC_000008.11:g.18400295G>A	gnomAD
rs764673578	p.Asn99Asp	missense variant	-	NC_000008.11:g.18400298A>G	ExAC,gnomAD
NCI-TCGA novel	p.Lys100Glu	missense variant	-	NC_000008.11:g.18400301A>G	NCI-TCGA
rs1200849934	p.Tyr101His	missense variant	-	NC_000008.11:g.18400304T>C	gnomAD
rs1225528067	p.Tyr101Ter	stop gained	-	NC_000008.11:g.18400305dup	TOPMed
rs749903527	p.Thr103Ser	missense variant	-	NC_000008.11:g.18400311C>G	ExAC,gnomAD
rs1445503066	p.Gly104Ser	missense variant	-	NC_000008.11:g.18400313G>A	gnomAD
rs757987716	p.Met105Leu	missense variant	-	NC_000008.11:g.18400316A>T	ExAC,gnomAD
COSM1699776	p.Val106Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400320T>C	NCI-TCGA Cosmic
rs549917500	p.His107Gln	missense variant	-	NC_000008.11:g.18400324C>A	1000Genomes,ExAC,gnomAD
rs751243960	p.Leu108Arg	missense variant	-	NC_000008.11:g.18400326T>G	ExAC,gnomAD
NCI-TCGA novel	p.Gln111Arg	missense variant	-	NC_000008.11:g.18400335A>G	NCI-TCGA
rs754884737	p.Gln111His	missense variant	-	NC_000008.11:g.18400336G>C	ExAC,gnomAD
rs1383708687	p.Val112Met	missense variant	-	NC_000008.11:g.18400337G>A	gnomAD
rs1801280	p.Ile114Thr	missense variant	-	NC_000008.11:g.18400344T>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs781102691	p.Ile114Val	missense variant	-	NC_000008.11:g.18400343A>G	ExAC,gnomAD
rs183409091	p.Gly116Ser	missense variant	-	NC_000008.11:g.18400349G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs879610883	p.Arg117Ser	missense variant	-	NC_000008.11:g.18400354G>T	gnomAD
rs749323416	p.Arg117Thr	missense variant	-	NC_000008.11:g.18400353G>C	ExAC,gnomAD
rs1349204233	p.Asn118Ser	missense variant	-	NC_000008.11:g.18400356A>G	TOPMed
rs1233619276	p.Asn118Asp	missense variant	-	NC_000008.11:g.18400355A>G	gnomAD
rs1405169350	p.Ile120Val	missense variant	-	NC_000008.11:g.18400361A>G	TOPMed
rs4986996	p.Asp122His	missense variant	-	NC_000008.11:g.18400367G>C	ExAC,TOPMed,gnomAD
rs559660817	p.Asp122Gly	missense variant	-	NC_000008.11:g.18400368A>G	ExAC,TOPMed,gnomAD
rs4986996	p.Asp122Tyr	missense variant	-	NC_000008.11:g.18400367G>T	ExAC,TOPMed,gnomAD
rs4986996	p.Asp122Asn	missense variant	-	NC_000008.11:g.18400367G>A	ExAC,TOPMed,gnomAD
rs1243197391	p.Ala123Val	missense variant	-	NC_000008.11:g.18400371C>T	TOPMed
NCI-TCGA novel	p.Ala123Asp	missense variant	-	NC_000008.11:g.18400371C>A	NCI-TCGA
rs764591879	p.Gly124Val	missense variant	-	NC_000008.11:g.18400374G>T	ExAC,TOPMed,gnomAD
rs764591879	p.Gly124Glu	missense variant	-	NC_000008.11:g.18400374G>A	ExAC,TOPMed,gnomAD
COSM4545381	p.Gly126Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400379G>A	NCI-TCGA Cosmic
rs140983217	p.Ser127Arg	missense variant	-	NC_000008.11:g.18400384C>A	ESP,ExAC,TOPMed,gnomAD
rs140983217	p.Ser127Arg	missense variant	-	NC_000008.11:g.18400384C>G	ESP,ExAC,TOPMed,gnomAD
rs1181461804	p.Ser128Tyr	missense variant	-	NC_000008.11:g.18400386C>A	gnomAD
rs754657440	p.Met131Ile	missense variant	-	NC_000008.11:g.18400396G>T	ExAC,TOPMed,gnomAD
rs754657440	p.Met131Ile	missense variant	-	NC_000008.11:g.18400396G>C	ExAC,TOPMed,gnomAD
rs754657440	p.Met131Ile	missense variant	-	NC_000008.11:g.18400396G>A	ExAC,TOPMed,gnomAD
rs767445699	p.Trp132Cys	missense variant	-	NC_000008.11:g.18400399G>C	ExAC,gnomAD
COSM3929475	p.Gln133His	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400402G>C	NCI-TCGA Cosmic
rs752501077	p.Pro134Ser	missense variant	-	NC_000008.11:g.18400403C>T	ExAC
NCI-TCGA novel	p.Pro134AlaPheSerTerUnkUnk	frameshift	-	NC_000008.11:g.18400401_18400402insG	NCI-TCGA
rs752501077	p.Pro134Ser	missense variant	-	NC_000008.11:g.18400403C>T	NCI-TCGA,NCI-TCGA Cosmic
rs1323316428	p.Leu135Pro	missense variant	-	NC_000008.11:g.18400407T>C	gnomAD
rs12720065	p.Leu135Val	missense variant	-	NC_000008.11:g.18400406C>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs4986997	p.Leu137Phe	missense variant	-	NC_000008.11:g.18400414A>C	ExAC,gnomAD
rs1392723145	p.Leu137Ser	missense variant	-	NC_000008.11:g.18400413T>C	gnomAD
rs4986997	p.Leu137Phe	missense variant	-	NC_000008.11:g.18400414A>T	ExAC,gnomAD
rs1328178338	p.Ile138Leu	missense variant	-	NC_000008.11:g.18400415A>C	TOPMed,gnomAD
rs749172780	p.Gly140Arg	missense variant	-	NC_000008.11:g.18400421G>A	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Gly140Ala	missense variant	-	NC_000008.11:g.18400422G>C	NCI-TCGA
rs778936592	p.Lys141Gln	missense variant	-	NC_000008.11:g.18400424A>C	ExAC,gnomAD
rs1413819756	p.Asp142Glu	missense variant	-	NC_000008.11:g.18400429T>A	gnomAD
COSM1331082	p.Gln143Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000008.11:g.18400430C>T	NCI-TCGA Cosmic
rs775833318	p.Gln145His	missense variant	-	NC_000008.11:g.18400438G>C	ExAC,gnomAD
rs72554616	p.Gln145Pro	missense variant	-	NC_000008.11:g.18400437A>C	ExAC,gnomAD
rs72554616	p.Gln145Pro	missense variant	-	NC_000008.11:g.18400437A>C	UniProt,dbSNP
VAR_009076	p.Gln145Pro	missense variant	-	NC_000008.11:g.18400437A>C	UniProt
rs1432822488	p.Gln145Lys	missense variant	-	NC_000008.11:g.18400436C>A	TOPMed
rs1357210737	p.Pro147Ser	missense variant	-	NC_000008.11:g.18400442C>T	gnomAD
NCI-TCGA novel	p.Ile149AsnPheSerTerUnkUnk	frameshift	-	NC_000008.11:g.18400447_18400448insA	NCI-TCGA
rs747336755	p.Cys151Arg	missense variant	-	NC_000008.11:g.18400454T>C	ExAC,gnomAD
rs1319339483	p.Leu152Phe	missense variant	-	NC_000008.11:g.18400459G>C	TOPMed
rs374177543	p.Leu152Trp	missense variant	-	NC_000008.11:g.18400458T>G	ESP,ExAC,TOPMed,gnomAD
rs72466460	p.Thr153Ile	missense variant	-	NC_000008.11:g.18400461C>T	TOPMed,gnomAD
NCI-TCGA novel	p.Glu155Gln	missense variant	-	NC_000008.11:g.18400466G>C	NCI-TCGA
rs368704280	p.Glu155Asp	missense variant	-	NC_000008.11:g.18400468G>C	ESP,ExAC,gnomAD
rs1162331328	p.Arg156Lys	missense variant	-	NC_000008.11:g.18400470G>A	gnomAD
rs770612696	p.Gly157Glu	missense variant	-	NC_000008.11:g.18400473G>A	ExAC,gnomAD
rs139351995	p.Ile158Leu	missense variant	-	NC_000008.11:g.18400475A>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs537007806	p.Trp159Arg	missense variant	-	NC_000008.11:g.18400478T>A	1000Genomes,TOPMed,gnomAD
rs537007806	p.Trp159Arg	missense variant	-	NC_000008.11:g.18400478T>C	1000Genomes,TOPMed,gnomAD
rs1035625458	p.Asp162Glu	missense variant	-	NC_000008.11:g.18400489C>G	TOPMed
rs139512288	p.Ile164Thr	missense variant	-	NC_000008.11:g.18400494T>C	1000Genomes,ExAC,gnomAD
COSM3646980	p.Arg165Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400497G>A	NCI-TCGA Cosmic
rs1315076417	p.Arg166Gly	missense variant	-	NC_000008.11:g.18400499A>G	gnomAD
rs1354992629	p.Arg166Thr	missense variant	-	NC_000008.11:g.18400500G>C	gnomAD
rs72554617	p.Glu167Gln	missense variant	-	NC_000008.11:g.18400502G>C	1000Genomes,ExAC,TOPMed,gnomAD
rs72554617	p.Glu167Lys	missense variant	-	NC_000008.11:g.18400502G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs1315180839	p.Gln168His	missense variant	-	NC_000008.11:g.18400507G>C	TOPMed,gnomAD
rs200585149	p.Tyr169Cys	missense variant	-	NC_000008.11:g.18400509A>G	1000Genomes
rs1341104335	p.Tyr169Asp	missense variant	-	NC_000008.11:g.18400508T>G	gnomAD
rs956044329	p.Thr171Ile	missense variant	-	NC_000008.11:g.18400515C>T	TOPMed
rs1010029101	p.Lys173Gln	missense variant	-	NC_000008.11:g.18400520A>C	TOPMed,gnomAD
rs369500066	p.Lys173Arg	missense variant	-	NC_000008.11:g.18400521A>G	ExAC,TOPMed,gnomAD
rs753856548	p.Glu174Lys	missense variant	-	NC_000008.11:g.18400523G>A	ExAC,gnomAD
NCI-TCGA novel	p.Leu176Phe	missense variant	-	NC_000008.11:g.18400529C>T	NCI-TCGA
rs757090914	p.Asn177Lys	missense variant	-	NC_000008.11:g.18400534T>G	ExAC,TOPMed,gnomAD
rs968770218	p.Ser178Tyr	missense variant	-	NC_000008.11:g.18400536C>A	TOPMed
NCI-TCGA novel	p.His179Tyr	missense variant	-	NC_000008.11:g.18400538C>T	NCI-TCGA
rs572750517	p.His179Arg	missense variant	-	NC_000008.11:g.18400539A>G	1000Genomes
rs778993761	p.Leu180Phe	missense variant	-	NC_000008.11:g.18400541C>T	ExAC,gnomAD
rs1232810154	p.Lys183Glu	missense variant	-	NC_000008.11:g.18400550A>G	TOPMed
rs1484935093	p.Lys183Thr	missense variant	-	NC_000008.11:g.18400551A>C	gnomAD
COSM3898586	p.Lys184Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400554A>C	NCI-TCGA Cosmic
rs1311332863	p.His186Tyr	missense variant	-	NC_000008.11:g.18400559C>T	TOPMed
NCI-TCGA novel	p.Gln187His	missense variant	-	NC_000008.11:g.18400564A>C	NCI-TCGA
rs372084377	p.Gln187Glu	missense variant	-	NC_000008.11:g.18400562C>G	ESP,ExAC,TOPMed
rs780311376	p.Ile189Met	missense variant	-	NC_000008.11:g.18400570A>G	ExAC,gnomAD
rs541628619	p.Ile189Thr	missense variant	-	NC_000008.11:g.18400569T>C	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Ile189AsnPheSerTerUnkUnk	frameshift	-	NC_000008.11:g.18400569T>-	NCI-TCGA
rs374761885	p.Tyr190Cys	missense variant	-	NC_000008.11:g.18400572A>G	ESP,ExAC,TOPMed,gnomAD
rs769102650	p.Tyr190Ter	stop gained	-	NC_000008.11:g.18400573C>G	ExAC,gnomAD
rs1388170814	p.Tyr190His	missense variant	-	NC_000008.11:g.18400571T>C	gnomAD
rs79050330	p.Thr193Met	missense variant	-	NC_000008.11:g.18400581C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Thr193Ala	missense variant	-	NC_000008.11:g.18400580A>G	NCI-TCGA
rs79050330	p.Thr193Met	missense variant	-	NC_000008.11:g.18400581C>T	NCI-TCGA,NCI-TCGA Cosmic
rs774002627	p.Leu194Val	missense variant	-	NC_000008.11:g.18400583C>G	ExAC,TOPMed,gnomAD
rs1381655226	p.Leu194Pro	missense variant	-	NC_000008.11:g.18400584T>C	gnomAD
rs759059031	p.Glu195Gln	missense variant	-	NC_000008.11:g.18400586G>C	ExAC,gnomAD
rs775284097	p.Pro196Arg	missense variant	-	NC_000008.11:g.18400590C>G	ExAC,gnomAD
rs771698130	p.Pro196Thr	missense variant	-	NC_000008.11:g.18400589C>A	ExAC,TOPMed,gnomAD
rs1799930	p.Arg197Gln	missense variant	-	NC_000008.11:g.18400593G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1799930	p.Arg197Gln	missense variant	-	NC_000008.11:g.18400593G>A	UniProt,dbSNP
VAR_004610	p.Arg197Gln	missense variant	-	NC_000008.11:g.18400593G>A	UniProt
rs375746304	p.Arg197Ter	stop gained	-	NC_000008.11:g.18400592C>T	ESP,ExAC,TOPMed,gnomAD
rs1390083945	p.Thr198Arg	missense variant	-	NC_000008.11:g.18400596C>G	TOPMed
rs761741098	p.Ile199Thr	missense variant	-	NC_000008.11:g.18400599T>C	ExAC,TOPMed,gnomAD
rs761741098	p.Ile199Asn	missense variant	-	NC_000008.11:g.18400599T>A	ExAC,TOPMed,gnomAD
COSM3646981	p.Glu200Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400601G>A	NCI-TCGA Cosmic
rs1483375862	p.Glu200Ter	stop gained	-	NC_000008.11:g.18400601G>T	gnomAD
rs750343726	p.Asp201Tyr	missense variant	-	NC_000008.11:g.18400604G>T	ExAC,TOPMed,gnomAD
rs750343726	p.Asp201Asn	missense variant	-	NC_000008.11:g.18400604G>A	ExAC,TOPMed,gnomAD
rs1450863488	p.Phe202Ser	missense variant	-	NC_000008.11:g.18400608T>C	gnomAD
rs45618543	p.Glu203Asp	missense variant	-	NC_000008.11:g.18400612G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs758539294	p.Glu203Gln	missense variant	-	NC_000008.11:g.18400610G>C	ExAC,TOPMed,gnomAD
rs45618543	p.Glu203Asp	missense variant	-	NC_000008.11:g.18400612G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1481100252	p.Glu203Gly	missense variant	-	NC_000008.11:g.18400611A>G	TOPMed
rs755105691	p.Ser204Tyr	missense variant	-	NC_000008.11:g.18400614C>A	ExAC,gnomAD
rs45607939	p.Met205Leu	missense variant	-	NC_000008.11:g.18400616A>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs531322433	p.Met205Ile	missense variant	-	NC_000008.11:g.18400618G>C	ExAC,gnomAD
rs45607939	p.Met205Val	missense variant	-	NC_000008.11:g.18400616A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1318865257	p.Tyr208Cys	missense variant	-	NC_000008.11:g.18400626A>G	gnomAD
rs56387565	p.Tyr208His	missense variant	-	NC_000008.11:g.18400625T>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1246640246	p.Leu209Arg	missense variant	-	NC_000008.11:g.18400629T>G	TOPMed
rs1370491254	p.Gln210Lys	missense variant	-	NC_000008.11:g.18400631C>A	gnomAD
rs749810939	p.Thr211Met	missense variant	-	NC_000008.11:g.18400635C>T	ExAC,TOPMed,gnomAD
rs749810939	p.Thr211Lys	missense variant	-	NC_000008.11:g.18400635C>A	ExAC,TOPMed,gnomAD
rs749810939	p.Thr211Met	missense variant	-	NC_000008.11:g.18400635C>T	NCI-TCGA,NCI-TCGA Cosmic
rs138707146	p.Pro213Leu	missense variant	-	NC_000008.11:g.18400641C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs568110818	p.Phe217Tyr	missense variant	-	NC_000008.11:g.18400653T>A	1000Genomes,ExAC,gnomAD
rs1231891119	p.Ile218Val	missense variant	-	NC_000008.11:g.18400655A>G	gnomAD
rs376918049	p.Thr219Ser	missense variant	-	NC_000008.11:g.18400658A>T	ESP,ExAC,gnomAD
rs761651231	p.Thr220Ile	missense variant	-	NC_000008.11:g.18400662C>T	ExAC,gnomAD
NCI-TCGA novel	p.Ser221Ala	missense variant	-	NC_000008.11:g.18400664T>G	NCI-TCGA
COSM4818209	p.Ser221Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400665C>T	NCI-TCGA Cosmic
rs1265895628	p.Cys223Ser	missense variant	-	NC_000008.11:g.18400671G>C	gnomAD
rs765010993	p.Cys223Ser	missense variant	-	NC_000008.11:g.18400670T>A	ExAC
rs1344597702	p.Cys223Trp	missense variant	-	NC_000008.11:g.18400672T>G	TOPMed,gnomAD
NCI-TCGA novel	p.Ser224Phe	missense variant	-	NC_000008.11:g.18400674C>T	NCI-TCGA
rs762854719	p.Leu225Ter	stop gained	-	NC_000008.11:g.18400677T>A	ExAC,gnomAD
COSM75560	p.Leu225Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400677T>C	NCI-TCGA Cosmic
rs150329557	p.Pro228Ser	missense variant	-	NC_000008.11:g.18400685C>T	ESP,ExAC,TOPMed,gnomAD
rs45518335	p.Pro228Leu	missense variant	-	NC_000008.11:g.18400686C>T	UniProt,dbSNP
VAR_018854	p.Pro228Leu	missense variant	-	NC_000008.11:g.18400686C>T	UniProt
rs45518335	p.Pro228Leu	missense variant	-	NC_000008.11:g.18400686C>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs755233460	p.Glu229Gly	missense variant	-	NC_000008.11:g.18400689A>G	ExAC,TOPMed,gnomAD
rs749948990	p.Gly230Val	missense variant	-	NC_000008.11:g.18400692G>T	ExAC,TOPMed,gnomAD
rs752955201	p.Val231Ile	missense variant	-	NC_000008.11:g.18400694G>A	ExAC,TOPMed,gnomAD
rs1157192529	p.Tyr232Ter	stop gained	-	NC_000008.11:g.18400699C>A	gnomAD
rs1157192529	p.Tyr232Ter	stop gained	-	NC_000008.11:g.18400699C>G	gnomAD
rs1414496827	p.Cys233Ser	missense variant	-	NC_000008.11:g.18400701G>C	TOPMed,gnomAD
rs756616433	p.Val235Gly	missense variant	-	NC_000008.11:g.18400707T>G	ExAC,gnomAD
rs1252922818	p.Val235Leu	missense variant	-	NC_000008.11:g.18400706G>C	TOPMed
rs778253810	p.Gly236Arg	missense variant	-	NC_000008.11:g.18400709G>C	ExAC,TOPMed,gnomAD
rs778253810	p.Gly236Ser	missense variant	-	NC_000008.11:g.18400709G>A	ExAC,TOPMed,gnomAD
rs149460636	p.Gly236Asp	missense variant	-	NC_000008.11:g.18400710G>A	ESP,ExAC,TOPMed,gnomAD
rs149460636	p.Gly236Val	missense variant	-	NC_000008.11:g.18400710G>T	ESP,ExAC,TOPMed,gnomAD
rs757793253	p.Ile238Leu	missense variant	-	NC_000008.11:g.18400715A>C	ExAC,gnomAD
rs568250144	p.Thr240Ile	missense variant	-	NC_000008.11:g.18400722C>T	gnomAD
rs568250144	p.Thr240Asn	missense variant	-	NC_000008.11:g.18400722C>A	gnomAD
NCI-TCGA novel	p.Lys243Gln	missense variant	-	NC_000008.11:g.18400730A>C	NCI-TCGA
COSM486276	p.Phe244Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400733T>C	NCI-TCGA Cosmic
rs746441923	p.Asn245Ser	missense variant	-	NC_000008.11:g.18400737A>G	ExAC,TOPMed,gnomAD
rs776210861	p.Tyr246Cys	missense variant	-	NC_000008.11:g.18400740A>G	ExAC,gnomAD
rs1271976533	p.Lys247Glu	missense variant	-	NC_000008.11:g.18400742A>G	gnomAD
rs747765495	p.Asp248Asn	missense variant	-	NC_000008.11:g.18400745G>A	ExAC,gnomAD
rs904393746	p.Asn249Ser	missense variant	-	NC_000008.11:g.18400749A>G	TOPMed,gnomAD
rs769624189	p.Asn249His	missense variant	-	NC_000008.11:g.18400748A>C	ExAC,gnomAD
rs996188894	p.Thr250Lys	missense variant	-	NC_000008.11:g.18400752C>A	TOPMed,gnomAD
NCI-TCGA novel	p.Asp251Tyr	missense variant	-	NC_000008.11:g.18400754G>T	NCI-TCGA
rs772941387	p.Asp251Asn	missense variant	-	NC_000008.11:g.18400754G>A	ExAC,TOPMed,gnomAD
rs762908305	p.Val253Ala	missense variant	-	NC_000008.11:g.18400761T>C	ExAC,gnomAD
rs1473049060	p.Val253Ile	missense variant	-	NC_000008.11:g.18400760G>A	gnomAD
rs369191649	p.Glu254Lys	missense variant	-	NC_000008.11:g.18400763G>A	ESP,ExAC,TOPMed,gnomAD
rs55700793	p.Lys256Glu	missense variant	-	NC_000008.11:g.18400769A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs55700793	p.Lys256Ter	stop gained	-	NC_000008.11:g.18400769A>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs373698592	p.Thr257Ala	missense variant	-	NC_000008.11:g.18400772A>G	ESP,ExAC,TOPMed,gnomAD
rs373698592	p.Thr257Ser	missense variant	-	NC_000008.11:g.18400772A>T	ESP,ExAC,TOPMed,gnomAD
rs756385259	p.Thr257Ser	missense variant	-	NC_000008.11:g.18400773C>G	ExAC,gnomAD
rs764579294	p.Leu258Val	missense variant	-	NC_000008.11:g.18400775C>G	ExAC,gnomAD
rs1310257229	p.Thr259Ala	missense variant	-	NC_000008.11:g.18400778A>G	gnomAD
rs1304162037	p.Thr259Asn	missense variant	-	NC_000008.11:g.18400779C>A	TOPMed
rs1310257229	p.Thr259Ala	missense variant	-	NC_000008.11:g.18400778A>G	NCI-TCGA Cosmic
rs754185402	p.Glu260Lys	missense variant	-	NC_000008.11:g.18400781G>A	ExAC,gnomAD
rs757792034	p.Glu260Asp	missense variant	-	NC_000008.11:g.18400783G>C	ExAC,gnomAD
rs754185402	p.Glu260Gln	missense variant	-	NC_000008.11:g.18400781G>C	ExAC,gnomAD
rs1229559151	p.Glu261Gly	missense variant	-	NC_000008.11:g.18400785A>G	gnomAD
rs779344462	p.Glu262Asp	missense variant	-	NC_000008.11:g.18400789G>C	ExAC
rs968335980	p.Val263Ala	missense variant	-	NC_000008.11:g.18400791T>C	TOPMed,gnomAD
rs1290457380	p.Val263Ile	missense variant	-	NC_000008.11:g.18400790G>A	gnomAD
rs539346244	p.Val266Met	missense variant	-	NC_000008.11:g.18400799G>A	1000Genomes,ExAC,TOPMed,gnomAD
rs1208	p.Lys268Arg	missense variant	-	NC_000008.11:g.18400806=	UniProt,dbSNP
VAR_004611	p.Lys268Arg	missense variant	-	NC_000008.11:g.18400806=	UniProt
rs1208	p.Arg268Lys	missense variant	-	NC_000008.11:g.18400806G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs910738034	p.Arg268Gly	missense variant	-	NC_000008.11:g.18400805A>G	gnomAD
rs1208	p.Arg268Ile	missense variant	-	NC_000008.11:g.18400806G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
VAR_004611	p.Lys268Arg	Missense	-	-	UniProt
rs868725509	p.Ile270Thr	missense variant	-	NC_000008.11:g.18400812T>C	TOPMed,gnomAD
rs1235991376	p.Ile270Met	missense variant	-	NC_000008.11:g.18400813A>G	gnomAD
rs780656764	p.Phe271Leu	missense variant	-	NC_000008.11:g.18400814T>C	ExAC,TOPMed,gnomAD
rs1182548272	p.Lys272Glu	missense variant	-	NC_000008.11:g.18400817A>G	gnomAD
COSM3646982	p.Ser274Phe	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000008.11:g.18400824C>T	NCI-TCGA Cosmic
rs148566670	p.Leu275Met	missense variant	-	NC_000008.11:g.18400826T>A	ESP,ExAC,TOPMed,gnomAD
rs1448193837	p.Gly276Glu	missense variant	-	NC_000008.11:g.18400830G>A	gnomAD
rs1269922864	p.Gly276Arg	missense variant	-	NC_000008.11:g.18400829G>C	TOPMed
rs1448193837	p.Gly276Glu	missense variant	-	NC_000008.11:g.18400830G>A	NCI-TCGA
rs1434541633	p.Arg277Lys	missense variant	-	NC_000008.11:g.18400833G>A	gnomAD
rs980236111	p.Arg277Ter	stop gained	-	NC_000008.11:g.18400832A>T	TOPMed,gnomAD
rs777549905	p.Leu279Arg	missense variant	-	NC_000008.11:g.18400839T>G	ExAC,gnomAD
rs56393504	p.Val280Met	missense variant	-	NC_000008.11:g.18400841G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs56393504	p.Val280Leu	missense variant	-	NC_000008.11:g.18400841G>T	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1363900196	p.Pro281Thr	missense variant	-	NC_000008.11:g.18400844C>A	TOPMed,gnomAD
rs56054745	p.Lys282Thr	missense variant	-	NC_000008.11:g.18400848A>C	UniProt,dbSNP
VAR_009077	p.Lys282Thr	missense variant	-	NC_000008.11:g.18400848A>C	UniProt
rs56054745	p.Lys282Thr	missense variant	-	NC_000008.11:g.18400848A>C	ESP,ExAC,TOPMed,gnomAD
rs56054745	p.Lys282Arg	missense variant	-	NC_000008.11:g.18400848A>G	ESP,ExAC,TOPMed,gnomAD
rs772095430	p.Pro283Ala	missense variant	-	NC_000008.11:g.18400850C>G	ExAC,gnomAD
rs775667197	p.Pro283Arg	missense variant	-	NC_000008.11:g.18400851C>G	ExAC,gnomAD
rs1283582970	p.Asp285Gly	missense variant	-	NC_000008.11:g.18400857A>G	TOPMed
rs1799931	p.Gly286Glu	missense variant	-	NC_000008.11:g.18400860G>A	UniProt,dbSNP
VAR_004612	p.Gly286Glu	missense variant	-	NC_000008.11:g.18400860G>A	UniProt
rs1799931	p.Gly286Glu	missense variant	-	NC_000008.11:g.18400860G>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs72554618	p.Ser287Pro	missense variant	-	NC_000008.11:g.18400862T>C	ExAC
rs1211162895	p.Ser287Cys	missense variant	-	NC_000008.11:g.18400863C>G	gnomAD
rs762148940	p.Ile290Thr	missense variant	-	NC_000008.11:g.18400872T>C	ExAC,gnomAD
rs146801219	p.Ter291Glu	stop lost	-	NC_000008.11:g.18400874T>G	ESP,ExAC,TOPMed,gnomAD
rs750940890	p.Ter291Trp	stop lost	-	NC_000008.11:g.18400875A>G	ExAC,gnomAD

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001175	Acquired Immunodeficiency Syndrome	group	BEFREE
C0001418	Adenocarcinoma	group	BEFREE
C0001430	Adenoma	group	BEFREE;LHGDN
C0002395	Alzheimer's Disease	disease	BEFREE
C0002871	Anemia	disease	BEFREE
C0002893	Refractory anemias	disease	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE;LHGDN
C0004096	Asthma	disease	BEFREE
C0004114	Astrocytoma	disease	BEFREE
C0004943	Behcet Syndrome	disease	BEFREE
C0005684	Malignant neoplasm of urinary bladder	disease	BEFREE;CTD_human
C0005695	Bladder Neoplasm	group	BEFREE;CTD_human;LHGDN
C0006118	Brain Neoplasms	group	BEFREE;LHGDN
C0006142	Malignant neoplasm of breast	disease	BEFREE;CTD_human
C0006840	Candidiasis	disease	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007104	Female Breast Carcinoma	disease	BEFREE
C0007107	Malignant neoplasm of larynx	disease	BEFREE
C0007113	Rectal Carcinoma	disease	BEFREE
C0007115	Malignant neoplasm of thyroid	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE
C0007134	Renal Cell Carcinoma	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE;LHGDN
C0007847	Malignant tumor of cervix	disease	BEFREE
C0008350	Cholelithiasis	disease	BEFREE
C0008626	Congenital chromosomal disease	group	BEFREE
C0008924	Cleft upper lip	disease	LHGDN
C0009324	Ulcerative Colitis	disease	BEFREE
C0009375	Colonic Neoplasms	group	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009404	Colorectal Neoplasms	group	BEFREE;LHGDN
C0010054	Coronary Arteriosclerosis	disease	CTD_human
C0010346	Crohn Disease	disease	BEFREE;LHGDN
C0011268	Senile dementia	disease	BEFREE
C0011269	Dementia, Vascular	disease	BEFREE
C0011615	Dermatitis, Atopic	disease	LHGDN
C0011847	Diabetes	disease	BEFREE
C0011849	Diabetes Mellitus	group	BEFREE;LHGDN
C0011854	Diabetes Mellitus, Insulin-Dependent	disease	BEFREE
C0011860	Diabetes Mellitus, Non-Insulin-Dependent	disease	BEFREE
C0011881	Diabetic Nephropathy	disease	BEFREE
C0011999	Diastematomyelia	disease	CTD_human
C0013182	Drug Allergy	phenotype	BEFREE;CTD_human
C0013221	Drug toxicity	group	CTD_human
C0014175	Endometriosis	disease	BEFREE
C0014544	Epilepsy	disease	BEFREE
C0014859	Esophageal Neoplasms	group	BEFREE;LHGDN
C0015230	Exanthema	phenotype	BEFREE
C0016034	Breast Fibrocystic Disease	disease	BEFREE
C0016978	gallbladder neoplasm	disease	LHGDN
C0017551	Gilbert Disease (disorder)	disease	BEFREE
C0017563	Gingival Diseases	group	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018671	Head and Neck Neoplasms	group	LHGDN
C0019158	Hepatitis	disease	BEFREE;LHGDN
C0019159	Hepatitis A	disease	BEFREE
C0019163	Hepatitis B	disease	BEFREE
C0019193	Hepatitis, Toxic	disease	CTD_human
C0019693	HIV Infections	group	BEFREE
C0020179	Huntington Disease	disease	BEFREE
C0020538	Hypertensive disease	group	BEFREE
C0021364	Male infertility	disease	BEFREE
C0021390	Inflammatory Bowel Diseases	group	BEFREE
C0022661	Kidney Failure, Chronic	disease	RGD
C0023055	Laryngeal neoplasm	disease	LHGDN
C0023418	leukemia	disease	BEFREE;LHGDN
C0023434	Chronic Lymphocytic Leukemia	disease	BEFREE
C0023449	Acute lymphocytic leukemia	disease	BEFREE
C0023452	Childhood Acute Lymphoblastic Leukemia	disease	BEFREE;CTD_human
C0023453	Leukemia, Lymphocytic, Acute, L2	disease	CTD_human
C0023467	Leukemia, Myelocytic, Acute	disease	BEFREE
C0023470	Myeloid Leukemia	disease	BEFREE
C0023530	Leukopenia	disease	CTD_human
C0023532	Leukoplakia, Oral	disease	BEFREE
C0023891	Liver Cirrhosis, Alcoholic	disease	BEFREE
C0023895	Liver diseases	group	BEFREE
C0023903	Liver neoplasms	group	CTD_human
C0024115	Lung diseases	group	BEFREE
C0024117	Chronic Obstructive Airway Disease	disease	BEFREE;LHGDN
C0024121	Lung Neoplasms	group	LHGDN
C0024141	Lupus Erythematosus, Systemic	disease	BEFREE;LHGDN
C0024299	Lymphoma	group	BEFREE
C0024301	Lymphoma, Follicular	disease	BEFREE
C0024305	Lymphoma, Non-Hodgkin	disease	BEFREE;LHGDN
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0025286	Meningioma	disease	BEFREE
C0026640	Mouth Neoplasms	group	LHGDN
C0026764	Multiple Myeloma	disease	BEFREE
C0026848	Myopathy	group	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027794	Neural Tube Defects	group	BEFREE;CTD_human
C0027806	Neurenteric Cyst	disease	CTD_human
C0028754	Obesity	disease	BEFREE
C0028796	Dermatitis, Occupational	disease	CTD_human
C0029453	Osteopenia	disease	BEFREE
C0029925	Ovarian Carcinoma	disease	BEFREE
C0030297	Pancreatic Neoplasm	disease	LHGDN
C0030567	Parkinson Disease	disease	BEFREE;LHGDN
C0031090	Periodontal Diseases	group	BEFREE;LHGDN
C0032580	Adenomatous Polyposis Coli	disease	BEFREE
C0032584	polyps	phenotype	BEFREE
C0032914	Pre-Eclampsia	phenotype	LHGDN
C0033578	Prostatic Neoplasms	group	BEFREE;CTD_human;LHGDN
C0034885	Rectal Neoplasms	group	BEFREE
C0036341	Schizophrenia	disease	BEFREE
C0036421	Systemic Scleroderma	disease	BEFREE
C0038356	Stomach Neoplasms	group	LHGDN
C0040136	Thyroid Neoplasm	disease	LHGDN
C0041296	Tuberculosis	disease	BEFREE
C0041327	Tuberculosis, Pulmonary	disease	BEFREE
C0041755	Adverse reaction to drug	group	CTD_human
C0042769	Virus Diseases	group	BEFREE
C0079731	B-Cell Lymphomas	group	BEFREE
C0079744	Diffuse Large B-Cell Lymphoma	disease	BEFREE
C0080218	Tethered Cord Syndrome	disease	CTD_human
C0085096	Peripheral Vascular Diseases	group	BEFREE
C0085584	Encephalopathies	group	BEFREE
C0086445	Idiopathic Membranous Glomerulonephritis	disease	BEFREE
C0086457	Industrial Dermatosis	disease	CTD_human
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0152018	Esophageal carcinoma	disease	BEFREE
C0152234	Iniencephaly	disease	CTD_human
C0152426	Craniorachischisis	disease	CTD_human
C0153381	Malignant neoplasm of mouth	disease	BEFREE
C0153382	Malignant neoplasm of oropharynx	disease	BEFREE
C0153452	Malignant neoplasm of gallbladder	disease	BEFREE
C0155877	Allergic asthma	disease	BEFREE
C0162670	Mitochondrial Myopathies	group	BEFREE
C0162820	Dermatitis, Allergic Contact	disease	LHGDN
C0178874	Tumor Progression	phenotype	BEFREE
C0202236	Triglycerides measurement	phenotype	GWASDB
C0206677	Adenomatous Polyps	disease	BEFREE
C0206698	Cholangiocarcinoma	disease	LHGDN
C0206704	Carcinoma, Large Cell	disease	BEFREE
C0220624	Adult Brain Neoplasm	disease	BEFREE
C0220641	Lip and Oral Cavity Carcinoma	disease	BEFREE
C0221052	Chronic berylliosis	disease	BEFREE
C0235653	Malignant neoplasm of female breast	disease	BEFREE
C0235782	Gallbladder Carcinoma	disease	BEFREE
C0235974	Pancreatic carcinoma	disease	BEFREE
C0238462	Medullary carcinoma of thyroid	disease	BEFREE
C0242379	Malignant neoplasm of lung	disease	BEFREE
C0242383	Age related macular degeneration	disease	BEFREE
C0264423	Asthma, Occupational	disease	BEFREE
C0266453	Exencephaly	disease	CTD_human
C0266929	Chronic Periodontitis	disease	BEFREE
C0278701	Gastric Adenocarcinoma	disease	BEFREE
C0278996	Malignant Head and Neck Neoplasm	disease	BEFREE
C0279626	Squamous cell carcinoma of esophagus	disease	BEFREE
C0279680	Transitional cell carcinoma of bladder	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0280313	Squamous cell carcinoma of oropharynx	disease	BEFREE
C0280324	Laryngeal Squamous Cell Carcinoma	disease	BEFREE
C0302592	Cervix carcinoma	disease	BEFREE
C0333983	Hyperplastic Polyp	disease	BEFREE
C0341439	Chronic liver disease	group	BEFREE
C0344479	Spinal Cord Myelodysplasia	disease	CTD_human
C0345904	Malignant neoplasm of liver	disease	CTD_human
C0345967	Malignant mesothelioma	disease	BEFREE;CTD_human
C0346647	Malignant neoplasm of pancreas	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE;CTD_human
C0376670	Pancreatitis, Alcoholic	disease	BEFREE
C0497327	Dementia	disease	LHGDN
C0546837	Malignant neoplasm of esophagus	disease	BEFREE
C0549473	Thyroid carcinoma	disease	BEFREE
C0553694	Oropharyngeal disorders	group	BEFREE
C0595989	Carcinoma of larynx	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0677886	Epithelial ovarian cancer	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE;CTD_human
C0684249	Carcinoma of lung	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0699885	Carcinoma of bladder	disease	BEFREE
C0702169	Acrania	disease	CTD_human
C0741682	Premenopausal breast cancer	disease	BEFREE
C0747845	early pregnancy	phenotype	BEFREE
C0751688	Malignant Squamous Cell Neoplasm	disease	BEFREE
C0810364	Cleft Lip with or without Cleft Palate	disease	BEFREE
C0812413	Malignant Pleural Mesothelioma	disease	BEFREE
C0860207	Drug-Induced Liver Disease	disease	BEFREE;CTD_human
C0878544	Cardiomyopathies	group	BEFREE
C0949059	Polyp of large intestine	disease	BEFREE
C1140680	Malignant neoplasm of ovary	disease	BEFREE
C1257931	Mammary Neoplasms, Human	group	CTD_human
C1262760	Hepatitis, Drug-Induced	disease	BEFREE;CTD_human
C1302401	Adenoma of large intestine	disease	BEFREE
C1306460	Primary malignant neoplasm of lung	disease	BEFREE
C1319315	Adenocarcinoma of large intestine	disease	BEFREE
C1332338	Asbestos-Related Malignant Mesothelioma	disease	BEFREE
C1333990	Hereditary Nonpolyposis Colorectal Cancer	disease	BEFREE
C1337013	Differentiated Thyroid Gland Carcinoma	disease	BEFREE
C1384666	hearing impairment	phenotype	LHGDN
C1402315	Vascular lesions	disease	BEFREE
C1445957	Serum total cholesterol measurement	phenotype	GWASCAT
C1458155	Mammary Neoplasms	group	CTD_human;LHGDN
C1512409	Hepatocarcinogenesis	disease	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1565489	Renal Insufficiency	disease	BEFREE
C1621958	Glioblastoma Multiforme	disease	BEFREE
C1704436	Peripheral Arterial Diseases	group	BEFREE
C1762616	Meningioma, benign, no ICD-O subtype	disease	BEFREE
C1827377	Slow acetylator due to N-acetyltransferase enzyme variant	disease	BEFREE
C1827820	Fast acetylator due to N-acetyltransferase enzyme variant	disease	BEFREE
C1837217	Cleft lip, isolated	disease	BEFREE
C1840311	Laryngeal cleft	disease	BEFREE
C1956346	Coronary Artery Disease	disease	CTD_human
C1961102	Precursor Cell Lymphoblastic Leukemia Lymphoma	disease	CTD_human
C2239176	Liver carcinoma	disease	BEFREE
C2316810	Chronic kidney disease stage 5	disease	RGD
C2349952	Oropharyngeal Carcinoma	disease	BEFREE
C3266076	Orofacial cleft	disease	BEFREE
C3539909	Allergic disposition	phenotype	BEFREE
C3541994	Drug Hypersensitivity Syndrome	disease	BEFREE
C3642345	Luminal A Breast Carcinoma	disease	BEFREE
C3642346	Luminal B Breast Carcinoma	disease	BEFREE
C3658290	Drug-Induced Acute Liver Injury	disease	CTD_human
C3826066	Leukemia in children	disease	BEFREE
C3887461	Head and Neck Carcinoma	disease	BEFREE
C3899278	Early Rheumatoid Arthritis	disease	BEFREE
C4048328	cervical cancer	disease	BEFREE
C4054726	Infant Leukemia	disease	BEFREE
C4275179	Young onset Parkinson disease	disease	BEFREE
C4277682	Chemical and Drug Induced Liver Injury	disease	CTD_human
C4279912	Chemically-Induced Liver Toxicity	disease	CTD_human

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0004060	arylamine N-acetyltransferase activity	IBA
GO:0004060	arylamine N-acetyltransferase activity	TAS
GO:0005515	protein binding	IPI

GO:Biological Process

GO ID	GO Term	Evidence
GO:0006805	xenobiotic metabolic process	TAS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005829	cytosol	TAS

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-1430728	Metabolism	TAS
R-HSA-156580	Phase II - Conjugation of compounds	TAS
R-HSA-156582	Acetylation	TAS
R-HSA-211859	Biological oxidations	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C028474	1,4-bis(2-(3,5-dichloropyridyloxy))benzene	1,4-bis(2-(3,5-dichloropyridyloxy))benzene results in decreased expression of NAT2 mRNA	21354444
C015262	1,6-hexamethylene diisocyanate	NAT2 protein polymorphism results in increased susceptibility to 1,6-hexamethylene diisocyanate	11927838
C021183	1,7-dimethylxanthine	NAT2 protein results in increased metabolism of 1,7-dimethylxanthine	19215233
C021183	1,7-dimethylxanthine	[NAT2 protein results in increased metabolism of 1,7-dimethylxanthine] which results in increased chemical synthesis of 5-acetylamino-6-formylamino-3-methyluracil	19215233
C001042	2',3-dimethyl-4-aminobiphenyl	NAT2 gene affects the susceptibility to 2',3-dimethyl-4-aminobiphenyl	8564966; 8631131;
C001042	2',3-dimethyl-4-aminobiphenyl	NAT2 gene polymorphism affects the acetylation of 2',3-dimethyl-4-aminobiphenyl	12618593
C001042	2',3-dimethyl-4-aminobiphenyl	NAT2 protein results in increased acetylation of 2',3-dimethyl-4-aminobiphenyl	12618593; 8425184;
C001042	2',3-dimethyl-4-aminobiphenyl	NAT2 gene polymorphism affects the susceptibility to 2',3-dimethyl-4-aminobiphenyl	9356307
D015073	2-Acetylaminofluorene	NAT2 protein results in increased activity of 2-Acetylaminofluorene	15450435
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in decreased expression of NAT2 mRNA	22138251
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine results in increased expression of NAT2 mRNA	29549414
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein polymorphism results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	15110095
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased activity of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	15110095
C049584	2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased acetylation of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	19666988
C036989	2-amino-3,4-dimethylimidazo(4,5-f)quinoline	[CYP3A7 co-treated with NAT2] results in increased susceptibility to 2-amino-3,4-dimethylimidazo(4,5-f)quinoline	7625840
C036989	2-amino-3,4-dimethylimidazo(4,5-f)quinoline	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3,4-dimethylimidazo(4,5-f)quinoline	28160022
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	[CYP3A7 co-treated with NAT2] results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	7625840
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	28160022
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	[xanthohumol co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NAT2 mRNA	22138251
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	[Phenobarbital co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of NAT2 mRNA	23681119
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	NAT2 protein results in increased acetylation of 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	19666988
C036990	2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	NAT2 protein results in increased susceptibility to 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	19666988
C546460	2-amino-3-methyl-3H-imidazo(4,5-f)quinoline	2-amino-3-methyl-3H-imidazo(4,5-f)quinoline results in decreased expression of NAT2 mRNA	23810796
C017821	2-amino-3-methyl-9H-pyrido(2,3-b)indole	NAT2 protein results in increased activity of 2-amino-3-methyl-9H-pyrido(2,3-b)indole	14729582
C017821	2-amino-3-methyl-9H-pyrido(2,3-b)indole	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methyl-9H-pyrido(2,3-b)indole	28160022
C029216	2-amino-3-methylimidazo(4,5-f)quinoline	[CYP3A7 co-treated with NAT2] results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline	7625840
C029216	2-amino-3-methylimidazo(4,5-f)quinoline	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline	28160022
C029216	2-amino-3-methylimidazo(4,5-f)quinoline	NAT2 protein results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline	9150757
C029216	2-amino-3-methylimidazo(4,5-f)quinoline	[NAT2 protein results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoline] which results in increased mutagenesis of APRT gene	9150757
C432523	2-amino-3-methylimidazo(4,5-f)quinoxaline	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-3-methylimidazo(4,5-f)quinoxaline	28160022
C023785	2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-6-methyldipyrido(1,2-a-3',2'-d)imidazole	28160022
C017822	2-amino-9H-pyrido(2,3-b)indole	[CYP1A2 protein co-treated with NAT2 gene polymorphism] promotes the reaction [2-amino-9H-pyrido(2,3-b)indole binds to and results in increased mutagenesis of HPRT1 gene]	19243127
C017822	2-amino-9H-pyrido(2,3-b)indole	NAT2 gene polymorphism affects the susceptibility to 2-amino-9H-pyrido(2,3-b)indole	19243127
C017822	2-amino-9H-pyrido(2,3-b)indole	NAT2 protein results in increased metabolism of and results in increased susceptibility to 2-amino-9H-pyrido(2,3-b)indole	28160022
C012177	2-aminofluorene	NAT2 protein polymorphism results in increased acetylation of 2-aminofluorene	14722254
C012177	2-aminofluorene	NAT2 protein results in increased acetylation of 2-aminofluorene	12222688; 14722254;
C012177	2-aminofluorene	NAT2 protein results in increased metabolism of 2-aminofluorene	30358977
C012177	2-aminofluorene	NAT2 gene polymorphism affects the acetylation of 2-aminofluorene	12618593
C012177	2-aminofluorene	NAT2 protein results in increased acetylation of 2-aminofluorene	12618593; 15627487; 16003948; 8425184;
C012177	2-aminofluorene	[Cadmium Chloride results in decreased activity of NAT2 protein] which affects the acetylation of 2-aminofluorene	20810355
C012177	2-aminofluorene	NAT2 protein results in increased metabolism of 2-aminofluorene	16815960
C012177	2-aminofluorene	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 2-aminofluorene]	18842621
C012177	2-aminofluorene	NAT2 protein results in increased acetylation of 2-aminofluorene	18842621
C003898	2-anisidine	NAT2 protein results in increased activity of 2-anisidine	15450435
C075748	2-(bromoacetylamino)fluorene	2-(bromoacetylamino)fluorene binds to NAT2 protein	15106881
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	12222688
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	29596660
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	12618593
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	28536864
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine]	18842621
C060533	2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine	18842621
C032012	2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline	NAT2 protein results in increased acetylation of and results in increased activity of 2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline	12067565
D015081	2-Naphthylamine	NAT2 protein results in increased activity of 2-Naphthylamine	15450435
D015081	2-Naphthylamine	NAT2 gene polymorphism affects the acetylation of 2-Naphthylamine	12618593
D015081	2-Naphthylamine	NAT2 protein results in increased acetylation of 2-Naphthylamine	12618593
C012458	2-nitrosofluorene	2-nitrosofluorene results in decreased activity of NAT2 protein	19842618
C045421	3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine	NAT2 protein results in increased metabolism of and results in increased susceptibility to 3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine	28160022
C014464	3,4-dichloroaniline	NAT2 protein results in increased acetylation of 3,4-dichloroaniline	15627487
C068923	3,6-dinitrobenzopyrene	NAT2 protein results in increased metabolism of 3,6-dinitrobenzopyrene	19393727
C019133	3-amino-1-methyl-5H-pyrido(4,3-b)indole	NAT2 protein results in increased metabolism of and results in increased susceptibility to 3-amino-1-methyl-5H-pyrido(4,3-b)indole	28160022
C026137	3-hydroxyacetanilide	3-hydroxyacetanilide results in decreased expression of NAT2 mRNA	18544908
C117220	3-nitrobenzanthrone	[NAT2 protein co-treated with 3-nitrobenzanthrone] results in increased mutagenesis of HPRT1 gene	17483118
C117220	3-nitrobenzanthrone	[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]	20545351
C117220	3-nitrobenzanthrone	[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]	20545351
C117220	3-nitrobenzanthrone	NAT2 protein results in increased activity of 3-nitrobenzanthrone	15805261
C117220	3-nitrobenzanthrone	NAT2 protein results in increased susceptibility to 3-nitrobenzanthrone	17483118
C009505	4,4'-diaminodiphenylmethane	NAT2 gene polymorphism affects the acetylation of 4,4'-diaminodiphenylmethane	16192314
C009505	4,4'-diaminodiphenylmethane	NAT2 gene polymorphism results in increased susceptibility to 4,4'-diaminodiphenylmethane	16192314
C009505	4,4'-diaminodiphenylmethane	NAT2 protein results in increased acetylation of 4,4'-diaminodiphenylmethane	16192314
C005969	4,4'-diphenylmethane diisocyanate	NAT2 protein polymorphism results in increased susceptibility to 4,4'-diphenylmethane diisocyanate	11927838
D010129	4-Aminobenzoic Acid	NAT2 gene polymorphism affects the acetylation of 4-Aminobenzoic Acid	12618593
D010129	4-Aminobenzoic Acid	NAT2 protein results in increased acetylation of 4-Aminobenzoic Acid	12618593; 15627487; 16003948; 16482518;
D010129	4-Aminobenzoic Acid	NAT2 protein results in increased acetylation of 4-Aminobenzoic Acid	15627487
D010129	4-Aminobenzoic Acid	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 4-Aminobenzoic Acid]	18842621
D010129	4-Aminobenzoic Acid	NAT2 protein results in increased acetylation of 4-Aminobenzoic Acid	18842621
C026729	4-aminophenol	NAT2 protein results in increased acetylation of 4-aminophenol	8425184
C013813	4-anisidine	NAT2 protein results in increased acetylation of 4-anisidine	15627487
C006757	4-biphenylamine	NAT2 gene polymorphism affects the susceptibility to 4-biphenylamine	29180287
C006757	4-biphenylamine	NAT2 protein results in increased acetylation of 4-biphenylamine	12222688
C006757	4-biphenylamine	NAT2 protein results in increased activity of 4-biphenylamine	15450435
C006757	4-biphenylamine	NAT2 protein results in increased acetylation of 4-biphenylamine	16482518; 8425184;
C006757	4-biphenylamine	NAT2 protein results in increased metabolism of 4-biphenylamine	16815960; 16857729;
C006757	4-biphenylamine	NAT2 protein results in increased acetylation of 4-biphenylamine	28536864
C006757	4-biphenylamine	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 2-aminofluorene]	18842621
C006757	4-biphenylamine	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine]	18842621
C006757	4-biphenylamine	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 4-Aminobenzoic Acid]	18842621
C006757	4-biphenylamine	4-biphenylamine inhibits the reaction [NAT2 protein results in increased acetylation of 4-biphenylamine]	18842621
C006757	4-biphenylamine	4-biphenylamine results in decreased activity of NAT2 protein	18842621
C006757	4-biphenylamine	NAT2 protein results in increased acetylation of 4-biphenylamine	18842621
C023621	4-bromoaniline	NAT2 protein results in increased acetylation of 4-bromoaniline	15627487
C004658	4-chloroaniline	NAT2 protein results in increased acetylation of 4-chloroaniline	15627487
C072825	4-hexyloxyaniline	NAT2 protein results in increased acetylation of 4-hexyloxyaniline	15627487
C013067	4-iodoaniline	NAT2 protein results in increased acetylation of 4-iodoaniline	15627487
C008642	4-nitrophenyl acetate	NAT2 protein results in increased acetylation of 4-nitrophenyl acetate	15209520
C072328	4-nitrosobiphenyl	4-nitrosobiphenyl results in decreased activity of NAT2 protein	19842618
C029728	4-phenylenediamine	NAT2 gene polymorphism affects the susceptibility to 4-phenylenediamine	16533241
C036692	5-acetylamino-6-formylamino-3-methyluracil	[NAT2 protein results in increased metabolism of 1,7-dimethylxanthine] which results in increased chemical synthesis of 5-acetylamino-6-formylamino-3-methyluracil	19215233
C421010	9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole	NAT2 protein affects the metabolism of 9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole	17067997
C421010	9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole	NAT2 protein results in increased metabolism of and results in increased susceptibility to 9-(4'-aminophenyl)-9H-pyrido(3,4-b)indole	28160022
D000082	Acetaminophen	Acetaminophen results in decreased expression of NAT2 mRNA	21420995; 29067470;
D000082	Acetaminophen	Acetaminophen affects the expression of NAT2 mRNA	17562736
D000082	Acetaminophen	Acetaminophen results in decreased expression of NAT2 mRNA	18544908
D000105	Acetyl Coenzyme A	[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]	20545351
D000105	Acetyl Coenzyme A	[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]	20545351
C510884	acetylisoniazid	[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid	18544910
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of NAT2 mRNA	22100608
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of NAT2 mRNA	31542801
D016604	Aflatoxin B1	[CYP3A7 co-treated with NAT2] results in increased susceptibility to Aflatoxin B1	7625840
D000588	Amines	NAT2 protein affects the metabolism of and results in increased activity of Amines	12505289
D000588	Amines	NAT2 protein results in decreased activity of Amines	15613766
D000588	Amines	NAT2 protein results in increased acetylation of Amines	15122594
D000588	Amines	NAT2 protein results in increased activity of Amines	15700302
D010131	Aminosalicylic Acid	NAT2 protein results in increased acetylation of Aminosalicylic Acid	15627487; 16003948;
D010131	Aminosalicylic Acid	[Peroxynitrous Acid results in decreased activity of NAT2 protein] which results in decreased acetylation of Aminosalicylic Acid	19248797
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of NAT2 mRNA	16483693
C023650	aniline	NAT2 protein results in increased acetylation of aniline	15627487
D000814	Aniline Compounds	NAT2 protein results in increased acetylation of Aniline Compounds analog	15627487
D001194	Asbestos	NAT2 protein polymorphism affects the susceptibility to Asbestos	15993904
D001241	Aspirin	NAT2 polymorphism affects the susceptibility to Aspirin	20602614
D001397	Azoxymethane	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA	29950665
D001554	Benzene	NAT2 gene polymorphism affects the susceptibility to Benzene	15226677
D001554	Benzene	NAT2 gene polymorphism results in increased susceptibility to Benzene	15226677
D001554	Benzene	NAT2 protein affects the metabolism of Benzene	15226677
C029876	benzidine	NAT2 gene polymorphism affects the susceptibility to benzidine	16003747
C029876	benzidine	NAT2 protein results in increased acetylation of benzidine	28536864
D001564	Benzo(a)pyrene	[Benzo(a)pyrene co-treated with Butyric Acid] results in increased expression of NAT2 mRNA	30439556
D001564	Benzo(a)pyrene	[trichostatin A co-treated with Benzo(a)pyrene] results in increased expression of NAT2 mRNA	30439556
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of NAT2 mRNA	21715664
C006780	bisphenol A	bisphenol A binds to and results in decreased activity of NAT2 protein	18280460
C006780	bisphenol A	bisphenol A results in increased expression of NAT2 mRNA	25181051
C056005	bromoacetanilide	bromoacetanilide results in decreased activity of and results in increased alkylation of NAT2 protein	15106881
D020148	Butyric Acid	[Benzo(a)pyrene co-treated with Butyric Acid] results in increased expression of NAT2 mRNA	30439556
D020148	Butyric Acid	Butyric Acid results in increased expression of NAT2 mRNA	30439556
D019256	Cadmium Chloride	Cadmium Chloride binds to and results in decreased activity of NAT2 protein	20810355
D019256	Cadmium Chloride	Cadmium Chloride results in decreased activity of NAT2 protein	20810355
D019256	Cadmium Chloride	[Cadmium Chloride results in decreased activity of NAT2 protein] which affects the acetylation of 2-aminofluorene	20810355
D002110	Caffeine	NAT2 gene polymorphism affects the metabolism of Caffeine	24221535
D002110	Caffeine	NAT2 protein affects the metabolism of Caffeine	14586384; 14586387; 14747882; 15199075; 15327588; 15980104;
D002110	Caffeine	NAT2 protein results in increased acetylation of Caffeine	15558239
D002117	Calcitriol	Calcitriol results in decreased expression of NAT2 mRNA	27107558
D002117	Calcitriol	Calcitriol results in increased expression of NAT2 mRNA	21592394
D002117	Calcitriol	[Testosterone co-treated with Calcitriol] results in increased expression of NAT2 mRNA	21592394
D002220	Carbamazepine	Carbamazepine results in increased expression of NAT2 mRNA	17112801
D002338	Carotenoids	NAT2 protein polymorphism affects the susceptibility to Carotenoids	15095308
D002753	Chlorzoxazone	NAT2 protein affects the metabolism of Chlorzoxazone	14586387
D016572	Cyclosporine	Cyclosporine results in decreased expression of NAT2 mRNA	20106945; 27989131;
D016572	Cyclosporine	Cyclosporine results in decreased expression of NAT2 mRNA	19770486
D003622	Dapsone	NAT2 protein results in increased acetylation of Dapsone	14528063
D003622	Dapsone	NAT2 protein results in increased metabolism of Dapsone	15999287
C526360	dechlorane plus	dechlorane plus results in decreased expression of NAT2 mRNA	23245762
D003687	Dehydroepiandrosterone	Dehydroepiandrosterone results in decreased expression of NAT2 mRNA	18709148
D016264	Dextran Sulfate	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA	29950665
D003915	Dextromethorphan	NAT2 protein affects the metabolism of Dextromethorphan	15199075
C007366	diepoxybutane	NAT2 gene polymorphism results in decreased susceptibility to diepoxybutane	17078101
D004052	Diethylnitrosamine	Diethylnitrosamine results in increased expression of NAT2 mRNA	11323195
D004054	Diethylstilbestrol	Diethylstilbestrol results in decreased activity of NAT2 protein	18280460
C010920	dihydrofolate	dihydrofolate results in decreased activity of NAT2 protein	16003948
C066888	dimethocaine	NAT2 protein results in increased acetylation of dimethocaine	24309420
C096278	DNA-(2-amino-3-methylimidazo(4,5-f)quinoline) adduct	NAT2 protein affects the abundance of DNA-(2-amino-3-methylimidazo(4,5-f)quinoline) adduct	11470991
D004958	Estradiol	Estradiol results in decreased expression of NAT2 mRNA	20106945
D004958	Estradiol	Estradiol results in decreased expression of NAT2 mRNA	18709148
D005492	Folic Acid	Folic Acid results in decreased activity of NAT2 protein	16003948
D005492	Folic Acid	Folic Acid results in decreased activity of NAT2 protein modified form	16003948
D005492	Folic Acid	NAT2 protein results in increased acetylation of Folic Acid metabolite	15627487
D019833	Genistein	Genistein results in decreased activity of NAT2 protein	18280460
C023847	Glu-P-2	NAT2 protein results in increased metabolism of and results in increased susceptibility to Glu-P-2	28160022
C023847	Glu-P-2	NAT2 protein results in increased acetylation of Glu-P-2	8425184
C412815	GW 4064	GW 4064 promotes the reaction [NR1H4 protein binds to NAT2 gene]	20091679
D006202	Hair Dyes	NAT2 protein polymorphism affects the susceptibility to Hair Dyes	12663508
D006571	Heterocyclic Compounds	NAT2 protein affects the metabolism of and results in increased activity of Heterocyclic Compounds	12505289
D006830	Hydralazine	NAT2 protein affects the metabolism of Hydralazine	15627487
D006830	Hydralazine	NAT2 protein results in increased acetylation of Hydralazine	15627487
C029424	hydrazine	[NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine	18544910
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased activity of NAT2 protein	15644493
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased activity of NAT2 protein	19248797
D006881	Hydroxyacetylaminofluorene	Hydroxyacetylaminofluorene results in decreased activity of NAT2 protein	19842618
D007460	Iodoacetamide	Iodoacetamide results in decreased activity of NAT2 protein	22835378
D007460	Iodoacetamide	Iodoacetamide results in decreased activity of and results in increased alkylation of NAT2 protein	15209520
D007538	Isoniazid	NAT2 gene polymorphism affects the susceptibility to Isoniazid	11379777; 11915035; 15618686; 20485159;
D007538	Isoniazid	NAT2 gene polymorphism results in decreased acetylation of Isoniazid	18544910
D007538	Isoniazid	[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid	18544910
D007538	Isoniazid	[NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine	18544910
D007538	Isoniazid	NAT2 gene SNP affects the susceptibility to Isoniazid	25794903
D007538	Isoniazid	NAT2 protein affects the metabolism of Isoniazid	15627487
D007538	Isoniazid	NAT2 protein polymorphism affects the metabolism of Isoniazid	15546075; 15908628;
D007538	Isoniazid	NAT2 protein polymorphism results in increased acetylation of Isoniazid	17973219
D007538	Isoniazid	NAT2 protein results in increased acetylation of Isoniazid	11379777; 15565348; 15627487;
D007538	Isoniazid	NAT2 protein results in increased metabolism of Isoniazid	16531626; 16847467; 17509624; 30358977;
D007538	Isoniazid	NAT2 protein results in increased metabolism of Isoniazid	30358977
D007538	Isoniazid	Isoniazid results in decreased expression of NAT2 mRNA	28619387
D007538	Isoniazid	Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]	28619387
D007538	Isoniazid	[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA	28619387
D007538	Isoniazid	NAT2 protein affects the metabolism of Isoniazid	15855489
D007538	Isoniazid	NAT2 protein polymorphism affects the susceptibility to Isoniazid	15855489
D007538	Isoniazid	NAT2 protein results in increased metabolism of Isoniazid	17950035
D019804	Mesalamine	NAT2 protein results in increased acetylation of Mesalamine	15627487
D008727	Methotrexate	Methotrexate results in decreased activity of NAT2 protein	16003948
D008727	Methotrexate	Methotrexate results in decreased activity of NAT2 protein modified form	16003948
D008753	Methylenebis(chloroaniline)	Methylenebis(chloroaniline) binds to NAT2 protein	29180287
D008753	Methylenebis(chloroaniline)	NAT2 protein results in increased acetylation of Methylenebis(chloroaniline)	29180287
D008753	Methylenebis(chloroaniline)	NAT2 protein results in increased acetylation of Methylenebis(chloroaniline) analog	29180287
C568376	MT19c compound	MT19c compound results in increased expression of NAT2 mRNA	21781307
D009249	NADP	[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]	20545351
D037742	Nanotubes, Carbon	Nanotubes, Carbon results in increased expression of NAT2 mRNA	25554681
C016272	N-bromoacetamide	N-bromoacetamide results in decreased activity of and results in increased alkylation of NAT2 protein	15209520
C001368	N-hydroxy-2-aminofluorene	NAT2 protein results in increased acetylation of N-hydroxy-2-aminofluorene	12618593; 8425184;
C001365	N-hydroxy-4-acetylaminobiphenyl	N-hydroxy-4-acetylaminobiphenyl results in decreased activity of NAT2 protein	15720122
C001365	N-hydroxy-4-acetylaminobiphenyl	N-hydroxy-4-acetylaminobiphenyl results in decreased activity of NAT2 protein	19842618
C014593	N-hydroxy-4-aminobiphenyl	NAT2 protein results in increased acetylation of N-hydroxy-4-aminobiphenyl	12618593
C014593	N-hydroxy-4-aminobiphenyl	NAT2 protein results in increased metabolism of N-hydroxy-4-aminobiphenyl	16857729
C007350	nitrofen	NAT2 protein results in increased activity of nitrofen	14754874
C025589	ochratoxin A	ochratoxin A results in decreased expression of NAT2 mRNA	26505656
D010416	Pentachlorophenol	Pentachlorophenol results in decreased activity of NAT2 protein	29596660
C076994	perfluorooctane sulfonic acid	perfluorooctane sulfonic acid results in decreased expression of NAT2 mRNA	27153767
C023036	perfluorooctanoic acid	[perfluorooctanoic acid co-treated with PPARA] results in increased expression of NAT2 mRNA	20118188
C023036	perfluorooctanoic acid	perfluorooctanoic acid results in decreased expression of NAT2 mRNA	20118188
D030421	Peroxynitrous Acid	Peroxynitrous Acid results in decreased activity of NAT2 protein	15644493
D030421	Peroxynitrous Acid	Peroxynitrous Acid results in decreased activity of NAT2 protein	19248797
D030421	Peroxynitrous Acid	[Peroxynitrous Acid results in decreased activity of NAT2 protein] which results in decreased acetylation of Aminosalicylic Acid	19248797
D010634	Phenobarbital	[Phenobarbital co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in decreased expression of NAT2 mRNA	23681119
C030299	phenylhydrazine	NAT2 protein results in increased acetylation of phenylhydrazine	15627487
D010724	Phosphoadenosine Phosphosulfate	[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]	20545351
D011084	Polycyclic Aromatic Hydrocarbons	NAT2 gene polymorphism affects the secretion of Polycyclic Aromatic Hydrocarbons	21359562
D011084	Polycyclic Aromatic Hydrocarbons	NAT2 protein results in increased acetylation of Polycyclic Aromatic Hydrocarbons	15122594
C095911	polycyclic aromatic hydrocarbons-DNA adduct	NAT2 protein polymorphism results in increased abundance of polycyclic aromatic hydrocarbons-DNA adduct	11967624
D011342	Procainamide	NAT2 protein affects the acetylation of Procainamide	15930747
D011342	Procainamide	NAT2 protein results in increased acetylation of Procainamide	16003948
C035988	procymidone	procymidone results in increased expression of NAT2 mRNA	15686871
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of NAT2 mRNA	24780913
D011794	Quercetin	Quercetin results in increased activity of NAT2 protein	19215233
D012822	Silicon Dioxide	Silicon Dioxide results in decreased expression of NAT2 mRNA	19073995
D000077385	Silybin	Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]	28619387
D000077464	Simendan	NAT2 protein polymorphism results in increased acetylation of and results in increased activity of Simendan	15489122
D000077464	Simendan	NAT2 protein results in increased acetylation of and results in increased activity of Simendan	15489122
D012906	Smoke	NAT2 gene polymorphism affects the susceptibility to Smoke	19692670
C016104	sodium bichromate	sodium bichromate results in increased expression of NAT2 mRNA	12325037
D012969	Sodium Fluoride	Sodium Fluoride results in decreased expression of NAT2 mRNA	27862939
D013411	Sulfadiazine	NAT2 protein results in increased acetylation of Sulfadiazine	15843491
D013418	Sulfamethazine	NAT2 polymorphism affects the acetylation of Sulfamethazine	28516247
D013418	Sulfamethazine	NAT2 protein results in increased acetylation of Sulfamethazine	12222688; 15627487; 15880531; 21317369;
D013418	Sulfamethazine	NAT2 protein results in increased metabolism of Sulfamethazine	30358977
D013418	Sulfamethazine	NAT2 protein results in increased acetylation of Sulfamethazine	28536864
D013418	Sulfamethazine	NAT2 protein results in increased acetylation of Sulfamethazine	11470991
D013420	Sulfamethoxazole	NAT2 protein results in increased metabolism of Sulfamethoxazole	16847467
D013427	Sulfapyridine	NAT2 gene polymorphism affects the acetylation of Sulfapyridine	18167504
D013427	Sulfapyridine	NAT2 protein results in increased acetylation of Sulfapyridine	18167504
D012460	Sulfasalazine	NAT2 gene polymorphism affects the metabolism of Sulfasalazine	19560446
D012460	Sulfasalazine	NAT2 protein affects the metabolism of Sulfasalazine	15032315
D012460	Sulfasalazine	NAT2 protein affects the susceptibility to Sulfasalazine	15032315; 17377643; 17502830;
D012460	Sulfasalazine	NAT2 protein polymorphism affects the metabolism of Sulfasalazine	15032315
D012460	Sulfasalazine	NAT2 protein results in increased acetylation of Sulfasalazine	12465141
D012460	Sulfasalazine	NAT2 protein results in increased metabolism of Sulfasalazine	19560446
D013449	Sulfonamides	NAT2 protein affects the metabolism of Sulfonamides	15627487
D013629	Tamoxifen	Tamoxifen results in decreased activity of NAT2 protein	18280460
D000069459	Teas, Herbal	Teas, Herbal results in decreased activity of NAT2 protein	28011360
D013739	Testosterone	[Testosterone co-treated with Calcitriol] results in increased expression of NAT2 mRNA	21592394
D013739	Testosterone	Testosterone results in increased expression of NAT2 mRNA	21592394
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of NAT2 mRNA	19684285
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of NAT2 mRNA	21570461
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of NAT2 mRNA	18434241; 19933214;
C009495	titanium dioxide	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA	29950665
D014051	Toluene 2,4-Diisocyanate	NAT2 protein polymorphism results in increased susceptibility to Toluene 2,4-Diisocyanate	11927838
D014241	Trichloroethylene	NAT2 gene polymorphism results in increased susceptibility to Trichloroethylene	19834256
D014241	Trichloroethylene	Trichloroethylene results in decreased expression of NAT2 mRNA	19448997
C012589	trichostatin A	[trichostatin A co-treated with Benzo(a)pyrene] results in increased expression of NAT2 mRNA	30439556
C012589	trichostatin A	trichostatin A results in increased expression of NAT2 mRNA	24935251; 30439556;
D000077288	Troglitazone	Troglitazone results in increased expression of NAT2 mRNA	28973697
D014414	Tungsten	Tungsten results in increased expression of NAT2 mRNA	30912803
D014635	Valproic Acid	Valproic Acid affects the expression of NAT2 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of NAT2 mRNA	24935251; 28001369;
D001335	Vehicle Emissions	Vehicle Emissions affects the methylation of NAT2 gene	25560391
C025643	vinclozolin	vinclozolin results in increased expression of NAT2 mRNA	15686871
C029297	vinylidene chloride	vinylidene chloride results in decreased expression of NAT2 mRNA	26682919
C104536	xanthohumol	[xanthohumol co-treated with 2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline] results in increased expression of NAT2 mRNA	22138251
D015215	Zidovudine	Silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]	28619387
D015215	Zidovudine	[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA	28619387
D015215	Zidovudine	Zidovudine results in decreased expression of NAT2 mRNA	28619387

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0012	Acyltransferase
KW-0963	Cytoplasm
KW-0903	Direct protein sequencing
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0808	Transferase

Interpro

InterPro ID	InterPro Term
IPR001447	Arylamine_N-AcTrfase
IPR038765	Papain-like_cys_pep_sf

PROSITE

PROSITE ID	PROSITE Term

Pfam

Pfam ID	Pfam Term
PF00797	Acetyltransf_2

Gene: NAT2

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Identified variants/mutations related to cleft phenotype

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction